Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Epstein-Barr virus and multiple sclerosis: interaction with HLA

Genes & Immunity volume 13, pages 14–20 (2012)Cite this article

Abstract

Epstein-Barr virus (EBV) infection, history of infectious mononucleosis (IM) and HLA-A and DRB1 have all been proposed as risk factors for multiple sclerosis (MS). Our aim was to analyse possible interactions between antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA1) or EBNA1 fragments, presence of DRB1*15 and absence of A*02. The study population includes newly diagnosed cases and matched controls. Interaction on the additive scale was calculated using attributable proportion due to interaction (AP), which is the proportion of the incidence among individuals exposed to two interacting factors that is attributable to the interaction per se. IM showed association with MS, odds ratio (OR)=1.89 (1.45–2.48% confidence interval (CI)), as did raised EBNA1 IgG OR=1.74 (1.38–2.18 95%CI). All EBNA1 fragment IgGs were associated with MS risk. However, EBNA1 fragment 385–420 IgG levels were more strongly associated to MS than total EBNA1 IgG, OR=3.60 (2.75–4.72 95%CI), and also interacted with both DRB1*15 and absence of A*02, AP 0.60 (0.45–0.76 95%CI) and AP 0.39 (0.18–0.61 95%CI), respectively. The observed interaction between HLA class I and II genotype and reactivity to EBV-related epitopes suggest that the mechanism through which HLA genes influence the risk of MS may, at least in part, involve the immune control of EBV infection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Brynedal B, Duvefelt K, Jonasdottir G, Roos IM, Akesson E, Palmgren J et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2007; 2: e664.

    Article  Google Scholar 

  2. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV . Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010; 6: 156–166.

    Article  Google Scholar 

  3. Leibowitz U, Antonovsky A, Medalie JM, Smith HA, Halpern L, Alter M . Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 1966; 29: 60–68.

    Article  CAS  Google Scholar 

  4. Ascherio A, Munger KL . Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61: 288–299.

    Article  Google Scholar 

  5. Hunter SF, Hafler DA . Ubiquitous pathogens: Links between infection and autoimmunity in MS? Neurology 2000; 55: 164–165.

    Article  CAS  Google Scholar 

  6. Ascherio A, Munger KL . Epstein-barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 2010; 5: 271–277.

    Article  Google Scholar 

  7. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286: 3083–3088.

    Article  CAS  Google Scholar 

  8. Sundstrom P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nystrom L et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004; 62: 2277–2282.

    Article  CAS  Google Scholar 

  9. Sundstrom P, Nystrom M, Ruuth K, Lundgren E . Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. J Neuroimmunol 2009; 215: 102–107.

    Article  Google Scholar 

  10. Hosmer DW, Lemeshow S . Confidence interval estimation of interaction. Epidemiology 1992; 3: 452–456.

    Article  CAS  Google Scholar 

  11. Rothman KJ . Epidemiology: An Introduction. Oxford University Press: New York, NY, 2002, viii, 223pp.

    Google Scholar 

  12. Sundstrom P, Nystrom L, Jidell E, Hallmans G . EBNA-1 reactivity and HLA DRB1*1501 as statistically independent risk factors for multiple sclerosis: a case-control study. Mult Scler 2008; 14: 1120–1122.

    Article  CAS  Google Scholar 

  13. De Jager PL, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A . Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008; 70 (Pt 2): 1113–1118.

    Article  CAS  Google Scholar 

  14. Nielsen TR, Rostgaard K, Askling J, Steffensen R, Oturai A, Jersild C et al. Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult Scler 2009; 15: 431–436.

    Article  CAS  Google Scholar 

  15. Simon KC, van der Mei IA, Munger KL, Ponsonby A, Dickinson J, Dwyer T et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 2010; 74: 1365–1371.

    Article  CAS  Google Scholar 

  16. Goodin DS . The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One 2009; 4: e4565.

    Article  Google Scholar 

  17. Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A . Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67: 824–830.

    PubMed  PubMed Central  Google Scholar 

  18. Pender MP . Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev 2009; 8: 563–568.

    Article  CAS  Google Scholar 

  19. Niller HH, Wolf H, Minarovits J . Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008; 41: 298–328.

    Article  CAS  Google Scholar 

  20. Rand KH, Houck H, Denslow ND, Heilman KM . Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 65: 48–55.

    Article  CAS  Google Scholar 

  21. Steinman L . A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 2009; 9: 440–447.

    Article  CAS  Google Scholar 

  22. Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol 1997; 71: 4657–4662.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204: 2899–2912.

    Article  CAS  Google Scholar 

  24. Serafini B, Severa M, Columba-Cabezas S, Rosicarelli B, Veroni C, Chiappetta G et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 2010; 69: 677–693.

    Article  CAS  Google Scholar 

  25. Aloisi F, Serafini B, Magliozzi R, Howell OW, Reynolds R . Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain 2010; 133 (Pt 12): e157.

    Article  Google Scholar 

  26. Casiraghi C, Dorovini-Zis K, Horwitz MS . Epstein-Barr virus infection of human brain microvessel endothelial cells: a novel role in multiple sclerosis. J Neuroimmunol 2011; 230: 173–177.

    Article  CAS  Google Scholar 

  27. Zivadinov R, Weinstock-Guttman B, Zorzon M, Uxa L, Serafin M, Bosco A et al. Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol 2009; 209: 123–130.

    Article  CAS  Google Scholar 

  28. McAulay KA, Higgins CD, Macsween KF, Lake A, Jarrett RF, Robertson FL et al. HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. J Clin Invest 2007; 117: 3042–3048.

    Article  CAS  Google Scholar 

  29. Hjalgrim H, Rostgaard K, Johnson PC, Lake A, Shield L, Little AM et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci USA 2010; 107: 6400–6405.

    Article  CAS  Google Scholar 

  30. Luzuriaga K, Sullivan JL . Infectious mononucleosis. N Engl J Med 2010; 362: 1993–2000.

    Article  CAS  Google Scholar 

  31. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L . Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009; 73: 696–701.

    Article  Google Scholar 

  32. Ramagopalan SV, Knight JC, Ebers GC . Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurol 2009; 22: 219–225.

    Article  CAS  Google Scholar 

  33. Olerup O, Zetterquist H . HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225–235.

    Article  CAS  Google Scholar 

  34. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A . Calculating measures of biological interaction. Eur J Epidemiol 2005; 20: 575–579.

    Article  Google Scholar 

Download references

Acknowledgements

The study was supported by grants from the Swedish Association for Persons with Neurological Disabilities, The Swedish Research Council, The Söderbergs Foundation, the AFA foundation, the Swedish Foundation for Working Life and Social research and the FP6 program Neuropromise (LSHM-CT-2005-018637). We thank Nina Nordin and Karin Kai-Larsen for help with collecting data.

Author contributions: ES did HLA genotyping and the statistical analysis, provided figures and wrote the paper. PS provided reagents and performed the anti-EBV antibody measurements. ML did HLA genotyping. AKH collected clinical information on the EIMS participants. FA contributed to writing of the paper. IK supervised HLA genotyping and the statistical analysis. JH, LA and TO are responsible for the EIMS study and the design of the study. All authors contributed to the final paper.

Author information

Author notes

  1. I Kockum, L Alfredsson and T Olsson: These authors contributed equally to this paper

Authors and Affiliations

  1. Department of Clinical Neuroscience, Neuroimmunology Unit, Center for Molecular Medicine L8:05, Karolinska Institutet, Stockholm, Sweden

    E Sundqvist, M Lindén, I Kockum & T Olsson

  2. Department of Clinical Neuroscience, Umeå University, Umeå, Sweden

    P Sundström

  3. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

    A K Hedström & L Alfredsson

  4. Department of Cell Biology and Neuroscience, Istituto Superiore di Sanità, Rome, Italy

    F Aloisi

  5. Department of Clinical Neuroscience, Neurogenetics group, Center for Molecular Medicine L8:00, Karolinska Institutet, Stockholm, Sweden

    J Hillert

Authors
  1. E Sundqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Sundström
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Lindén
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A K Hedström
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Aloisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Hillert
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I Kockum
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Alfredsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Olsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Sundqvist.

Ethics declarations

Competing interests

Ms Sundqvist has received research support from the Swedish Association for Persons with Neurological Disabilities. Professor Hillert has received unrestricted research support from BiogenIdec, MerckSerono and Bayer Schering. Professor Alfredsson receives research support from the Swedish Medical Research Council (Dnr 521-2009-2596) and Swedish Council for Working life and Social Research (Dnr 2009-0650). Professor Tomas Olsson has received grant support for MS research from unrestricted grant support from BiogenIdec, Bayer, SanofiAventis and Merck, and also lecture fees and/or advisory board consultancies for the same companies. Other authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Genes and Immunity website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sundqvist, E., Sundström, P., Lindén, M. et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun 13, 14–20 (2012). https://doi.org/10.1038/gene.2011.42

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gene.2011.42

Keywords

Search

Advanced search

Quick links